The goal of this study is to evaluate the role of Somatropin and Dehydroepiandrosterone (DHEA) on ovarian reserve parameters and intracytoplasmic sperm injection (ICSI) outcome in poor ovarian responder.
The main question it aims to answer is:
Which intervention is more effective in increasing number and size of follicles? Participants will be followed 1 month before starting induction in growth hormone and 12 weeks for DHEA and through intracytoplasmic sperm injection (ICSI) cycle.

Start Date10 Oct 2025

Sponsor / Collaborator

Beni-Suef University

CTRI/2025/03/082315

/ Not yet recruitingPhase 2/3IIT

To comparative evaluation of the effect of local application of somatropin growth hormone on osseointegration and bone density around dental implant clinical and radiographic study - NIL

Start Date15 Mar 2025

Sponsor / Collaborator-

NCT05746650

/ RecruitingNot ApplicableIIT

Regulation of Protein Turnover in Connective Tissue From Muscle and Tendon Following Muscle Tissue Injury

The study is a 2-week human study where 40 patients who are scheduled to undergo reconstructive knee surgery are randomized to administration of GH or placebo following or without neuromuscular electrical stimulation of hamstring muscles.The overall aim is to determine, the role of muscle connective tissue protein synthesis in muscle injury and repair.

Start Date24 Feb 2023

Sponsor / Collaborator

Bispebjerg Hospital

100 Clinical Results associated with Somatropin (Merck Serono SA)

100 Translational Medicine associated with Somatropin (Merck Serono SA)

100 Patents (Medical) associated with Somatropin (Merck Serono SA)

153

Literatures (Medical) associated with Somatropin (Merck Serono SA)

01 Feb 2026·BMJ Open

Recombinant human growth hormone (rHGH) for muscle enhancement in knee osteoarthritis: protocol for a pilot, randomised placebo-controlled trial

Article

Author: Kiss, Alexander ; Shah, Ajay ; Burkhart, Timothy A ; Marks, Paul ; Whyne, Cari ; Tomescu, Sebastian ; Wasserstein, David N ; Ravi, Bheeshma ; Catapano, Michael

Introduction:

The management of active patients with symptomatic knee osteoarthritis (KnOA) who are too young for total knee arthroplasty poses a specific challenge to clinicians. Research studies show that improving quadriceps muscle strength improves pain and function; however, aspects of the disease render it difficult for patients to achieve and maintain improvements. Recombinant human growth hormone (rHGH) is shown to increase the magnitude and duration of muscle growth when combined with exercise treatment in adult populations. Hence, rHGH combined with physical therapy may provide meaningful benefits in the treatment of KnOA.

Methods and analysis:

This is a single-centre, double-blind, randomised trial to pilot a future Phase III trial from 2025 to 2028. Participants are aged 18–60 with clinical and radiographic evidence of isolated degenerative arthritis of the knee (patellofemoral or tibiofemoral). The investigational product is rHGH (Saizen (somatropin of rDNA origin, EMD Serono)) and a saline placebo. Participants will deliver the solution via subcutaneous injection area once per day at a dose of 0.5 mg HGH per body surface area (0.5 mg/m 2 ) for 6 weeks, alongside participation in a lower limb strengthening programme developed by rehabilitation specialists. 17 participants will be recruited into each study arm. The primary outcomes are feasibility (compliance with the study drug regimen for the 6-week administration period and enrolment rate) and safety (the proportion of minor and major adverse events between groups). The primary endpoint for these outcomes will be at 6 weeks. The secondary outcomes are knee extension strength, knee flexion strength, radiographic arthritis progression, thigh muscle circumference, MRI-measured quadriceps muscle volume and patient-reported outcome measures (Knee Osteoarthritis Outcome Score (KOOS), SF-20 and Tegner). The primary endpoint for these outcomes will be at 12 weeks, and the final endpoint will be 24 months, where final radiographic (X-ray) assessment will take place. The primary outcome of compliance will be a calculation of mean compliance between groups, which can be analysed as a t-test after the treatment period. A two-sample, two-sided t-test will compare the clinical (secondary) outcome of greatest interest: knee extension strength at baseline versus week 6 compared between treatment groups. Other secondary outcomes will be compared using a simple linear mixed-effects model. The χ 2 test will be used to determine whether the number of participants who made meaningful changes was different between groups. The null hypotheses are that the rHGH and placebo groups will have no difference in compliance rates, safety events, knee extension strength at 12 weeks and arthritis grade progression at 24 months.

Ethics and dissemination:

This study has been approved by the Sunnybrook Research Institute Research and Ethics Board (#6427) and received a no-objection letter from Health Canada Clinical Trials. The primary sponsor is the Sunnybrook Centre for Clinical Trial Studies (CCTS). The findings of this study will be published in a peer-reviewed journal and presented at orthopaedic conferences.

Trial registration number:

NCT07036003 .

01 Jan 2025·PLoS One

Persistence with daily growth hormone among children and adolescents with growth hormone deficiency in Japan.

Article

Author: Wajnrajch, Michael P ; Benjumea, Darrin ; Jhingran, Priti ; Wogen, Jenifer ; Alvir, Jose ; Takasawa, Kei ; Chen, Yong ; Loftus, Jane

BACKGROUND:

Pediatric growth hormone deficiency (pGHD) is treated with daily somatropin (recombinant human growth hormone) injections. High rates of discontinuation and poor adherence to treatment, which are associated with worse growth outcomes, have been documented previously, for example in the US and Europe. Discontinuation of somatropin has not yet been evaluated using real-world data in Japan.

OBJECTIVES:

To describe discontinuation of, and persistence to, daily somatropin treatment among children with pGHD in Japan.

METHODS:

This was a retrospective cohort study of children (≥3 and <16 years old) who were prescribed somatropin, using 2 Japan-based databases, Japan Medical Data Center (JMDC) and Medical Data Vision (MDV). Children were required to have ≥1 prescription for somatropin (first prescription = index date) within each study period (1 January 2002-30 September 2021 for JMDC and 1 January 2009-31 October 2021 for MDV) and ≥1 GHD diagnosis code without a somatropin prescription during the 6-months pre-index period. Children were required to be continuously enrolled in the database ≥6 months preceding and ≥3 months following index date. Children were followed for up to 48 months post-index. Early persistence was defined as the proportion of children with ≥1 refill of somatropin subsequent to the initial prescription. Discontinuation was defined as the first observation of a gap in therapy (using >60, > 90, and 120-day gap thresholds) between successive somatropin prescription fill dates. Persistence was defined as continuous refills of somatropin with no gaps in therapy. Time to discontinuation/non-persistence was evaluated using Kaplan-Meier methods, and Cox proportional hazards models identified predictors of time to discontinuation. This analysis utilized de-identified patient data from 2 large, Japanese-based retrospective databases; as such this study does not meet the requirements for institutional review board (IRB) review.

RESULTS:

Among the children included in this study (JMDC N = 452, MDV N = 573), most were male (JMDC 64.8%, MDV 60.0%). Mean age (standard deviation) was 8.8 (3.6) years in JMDC and 7.5 (3.6) years in MDV. Early persistence was high across both cohorts (JMDC 91.2%, MDV 83.4%). Using the 90-day gap definition for discontinuation, a sizable proportion of children discontinued over the follow-up period: JMDC 19% at 12 months, 35% at 48 months; and MDV 33% at 12 months, 54% at 48 months. Fewer discontinuations were observed with the 120-day gap definition (~16% at 48 months in JMDC, ~ 28% at 48 months in MDV) and more were observed with the 60-day gap definition (~67% at 48 months in JMDC, ~ 83% at 48 months in MDV). No meaningful predictors of discontinuation were identified.

CONCLUSIONS:

Despite high early persistence with somatropin, many children with pGHD in Japan were increasingly non-persistent over time: at 48 months post-index, at least 16% of children discontinued therapy, using the JDMC database and the most conservative measure of gap allowance. These results suggest a need for new strategies to support somatropin medication use over time among children with pGHD in Japan.

01 Jan 2025·HUMAN REPRODUCTION

Empirical use of growth hormone in IVF is useless: the largest randomized controlled trial

Article

Author: Tadevosyan, Artak ; Phillips, Simon ; Mourad, Ali ; Jamal, Wael ; Hemmings, Robert ; Kadoch, Isaac-Jacques

Abstract:

STUDY QUESTION:

Does adjuvant growth hormone (GH) therapy in GnRH antagonist cycles improve reproductive outcomes in the general IVF population?

SUMMARY ANSWER:

Empiric adjuvant GH therapy in GnRH antagonist cycles does not improve IVF stimulation results or reproductive outcomes, including implantation, miscarriage, and clinical pregnancy rates.

WHAT IS KNOWN ALREADY:

Previous evidence regarding the benefits of GH therapy in IVF cycles has been inconclusive due to the lack of well-designed, large-scale randomized controlled trials (RCTs) in the general IVF population.

STUDY DESIGN, SIZE, DURATION:

This is a phase III open-label RCT involving 288 patients undergoing antagonist IVF cycles at the Ovo clinic in Montreal, Canada, between June 2014 and January 2020. Patients were randomly assigned at a 1:1 ratio to either the GH or control group. The intervention group received daily 2.5 mg subcutaneous injections of GH from Day 1 of ovarian stimulation until the day of oocyte retrieval, while the control group received standard ovarian stimulation without any adjuvant therapy.

PARTICIPANTS/MATERIALS, SETTING, METHODS:

Patients were expected normal responders. All embryo transfers, both fresh and frozen, resulting from the studied IVF cycle were included in an intention-to-treat and per-protocol analyses. The primary outcome was the clinical pregnancy rate, while secondary outcomes included the number of retrieved oocytes, good-quality embryos, maturation, fertilization, implantation, and miscarriage rates.

MAIN RESULTS AND THE ROLE OF CHANCE:

A total of 288 patients were recruited and randomly assigned at a 1:1 ratio to either the GH or the control group. After excluding cycle cancellations and patients who did not undergo transfer, 105 patients remained in each group. The overall mean age was 38.0 years, the mean BMI was 25.11 kg/m2 and the mean anti-Müllerian hormone was 2.51 ng/ml. The cycle characteristics were similar between both groups. No differences were observed regarding the total dose of gonadotropins (4600 versus 4660 IU for the GH and control groups, respectively, P = 0.752), days of stimulation (11.4 versus 11.7 days, P = 0.118), and endometrial thickness (10.63 versus 10.94 mm, P = 0.372). Both the intention to treat (ITT) and per protocol analyses yielded similar results for stimulation outcomes. In the ITT analysis, no differences were found in the number of follicles ≥15 mm (7.8 versus 7.1, P = 0.212), retrieved oocytes (11.7 versus 11.2, P = 0.613), mature oocytes (8.5 versus 8.6, P = 0.851), maturation rate (73.8 versus 78.4%, P = 0.060), fertilization rate (64.3 versus 67.2%, P = 0.388), and good quality embryos (2.5 versus 2.6, P = 0.767). Reproductive outcomes in fresh embryo transfer showed no difference for implantation rate (38.2 versus 39.5%, P = 0.829), miscarriage rate (26.5 versus 31.1%, P = 0.653), clinical pregnancy rate (43.6 versus 50.0%, P = 0.406, rate difference, 95% CI: −0.06 [−0.22, 0.09]), and live birth rate (32.1 versus 33.3%, P = 0.860). The number of embryos needed to achieve a clinical pregnancy was 3.0 versus 2.5 in the GH and control groups, respectively. Similarly, reproductive outcomes in first frozen embryo transfer showed no difference for implantation rate (31.6 versus 45.3%, P = 0.178), miscarriage rate (28.6 versus 26.3%, P = 0.873), clinical pregnancy rate (35.1 versus 44.2%, P = 0.406, P = 0.356, rate difference, 95% CI: −0.09 [−0.28, 0.10]), and live birth rate (22.8 versus 32.6%, P = 0.277). The number of embryos needed to achieve a clinical pregnancy was 3.1 versus 2.4 in the GH and control groups, respectively.

LIMITATIONS, REASONS FOR CAUTION:

The study focused on expected normal responders, limiting its applicability to other patient populations such as poor responders.

WIDER IMPLICATIONS OF THE FINDINGS:

These findings suggest that adding GH therapy to ovarian stimulation in GnRH antagonist cycles may not benefit the general IVF population. Additional high-quality RCTs are warranted to identify subgroups of patients who might benefit from this treatment.

STUDY FUNDING/COMPETING INTEREST(S):

EMD Serono Inc., Mississauga, Canada, supplied Saizen® for the study, free of charge. In addition, they provided funding for the statistical analysis. I-J.K. declares grants or contracts from Ferring Pharmaceuticals, consulting fees from Ferring Pharmaceuticals, honoraria from Ferring Pharmaceuticals and EMD Serono, support for attending meetings or travel from Ferring Pharmaceuticals and EMD Serono, participation on a Data Safety Monitoring Board or Advisory Board for Ferring Pharmaceuticals, and stock or stock options from The Fertility Partners; W.J. declares support for attending meetings or travel from EMD Serono; and S.P. declares stock or stock options from The Fertility Partners. All other authors have no conflicts of interest to disclose.

TRIAL REGISTRATION NUMBER:

NCT01715324.

TRIAL REGISTRATION DATE:

25 October 2012.

DATE OF FIRST PATIENT’S ENROLMENT:

25 June 2014.

News (Medical) associated with Somatropin (Merck Serono SA)

17 Feb 2026

·www.pharmaceutical-technology.com

Teijin and Aska Pharmaceutical agree for gynaecological drug development

Both companies share the goal of providing innovative treatments to improve quality of life for women with gynaecological conditions. Credit: Peakstock / Shutterstock.com. Teijin Pharma has signed a joint research agreement with Tokyo-based Aska Pharmaceutical to develop small-molecule drug candidates for gynaecological diseases. The collaboration aims to expedite early-stage drug discovery focused on innovative therapeutics, using Teijin Pharma’s expertise in computer-aided drug design (CADD) and AI. Under the agreement, both companies will focus on identifying “hit” compounds that interact with specific molecular targets. These initial compounds will undergo further optimisation to establish the desired efficacy, pharmacokinetic properties, and safety required for potential drug development. Teijin Pharma is advancing its drug candidate discovery process by enhancing simulation accuracy and predictive modelling, resulting in a research platform that shortens timelines and raises the probability of success in drug development. Aska Pharmaceutical brings experience grounded in addressing real-world clinical needs, particularly in women’s health, and has developed a portfolio focused on unmet medical requirements in the field. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence The company has developed a wide range of products to support women at various stages of life. The partnership will combine Teijin Pharma’s advanced drug discovery technologies with Aska Pharmaceutical’s clinical expertise in gynaecological disease evaluation. Both companies share the goal of providing innovative treatments to improve the quality of life for women with gynaecological conditions. Aska Pharmaceutical specialises in three areas: urology, internal medicine (gastroenterology and thyroid), and obstetrics and gynaecology. Teijin operates across high-performance materials and healthcare solutions worldwide, working with partners to deliver solutions aligned with its long-term vision. Teijin recently submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency seeking manufacturing and marketing approval for lonapegsomatropin, a prodrug of somatropin, which is administered once weekly.

29 Jul 2025

·www.pharmaceutical-technology.com

Ascendis Pharma’s Skytrofa gains FDA approval for growth hormone deficiency

The therapy is administered subcutaneously once a week, ensuring a sustained release of active, unmodified somatropin. Credit: Andrei Kuzmik / Shutterstock.com. The US Food and Drug Administration (FDA) has granted approval for Ascendis Pharma’s Skytrofa (lonapegsomatropin-tcgd, developed as TransCon hGH), a prodrug of somatropin or human growth hormone (HGH), to treat adults with growth hormone deficiency (GHD). GHD is characterised by a decrease or complete lack of production of endogenous growth hormone. Skytrofa was previously approved by the FDA in 2021 to treat children and paediatric patients aged one year or above weighing at least 11.5kg and are experiencing growth failure due to inadequate secretion of endogenous growth hormone (GH). It is a sterile, preservative-free lyophilised powder that appears white to off-white, available in a single-dose, dual-chamber prefilled cartridge. This therapy is administered subcutaneously once a week, ensuring a sustained release of active, unmodified somatropin. The FDA’s approval for adults with GHD was based on the findings from the Phase III parallel-arm, randomised, active-controlled (open-label) and placebo-controlled (double-blind) foresiGHt trial. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence It evaluated the safety and efficacy of weekly TransCon hGH in comparison to a weekly placebo and daily somatropin in adults diagnosed with GHD. Ascendis Pharma president and CEO Jan Mikkelsen said: “Our market research shows Skytrofa is the treatment of choice for paediatric GHD among patients and physicians, and we are pleased to expand its availability in the US for the treatment of adults initiating therapy or switching from another growth hormone therapy. “This important milestone is the first of many planned label expansions supporting our goal to become the leading endocrinology rare disease company.” Last year, the company submitted a supplemental biologics licence application to the FDA for TransCon hGH to treat adults with GHD. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

Phase 3Drug ApprovalClinical Result

28 Jul 2025

·pipelinereview.com

FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency

COPENHAGEN, Denmark I July 28, 2025 I Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has approved SKYTROFA ® (lonapegsomatropin-tcgd; developed as TransCon hGH) for the replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD), a rare disorder resulting from decreased or total loss of growth hormone production. Lonapegsomatropin (approved by the FDA in 2021 for the treatment of pediatric GHD) is a prodrug of somatropin (human growth hormone, or hGH) administered once weekly, providing sustained release of active, unmodified somatropin. The FDA’s approval of SKYTROFA for adult GHD was based on results from foresiGHt, a Phase 3 randomized, parallel-arm, placebo-controlled (double-blind) and active-controlled (open-label) clinical trial that compared the efficacy and safety of weekly TransCon hGH with weekly placebo and daily somatropin in adults with GHD. “The abnormal body composition, dyslipidemia, and insulin resistance that are the hallmarks of adult GHD predispose affected individuals to serious medical complications such as metabolic syndrome, increased cardiovascular risk, and impaired quality of life – including cognitive dysfunction, depression, anxiety, sleep disturbance, and reduced physical and mental drive. Despite this, adherence to daily somatropin injections that have been the standard of care for more than 25 years remains a problem,” said Kevin Yuen, M.D., Barrow Neurological Institute, University of Arizona College of Medicine and Creighton University School of Medicine in Phoenix, Arizona. “It is no surprise that patients are looking for a less burdensome treatment regimen, and a new treatment option such as SKYTROFA, with once-weekly injection and its unique release of unmodified somatropin, is expected to help improve both real-world adherence and overall outcomes.” “Our market research shows SKYTROFA is the treatment of choice for pediatric GHD among patients and physicians, and we are pleased to expand its availability in the United States for the treatment of adults initiating therapy or switching from another growth hormone therapy,” said Jan Mikkelsen, President and Chief Executive Officer at Ascendis Pharma. “This important milestone is the first of many planned label expansions supporting our goal to become the leading endocrinology rare disease company.” The following information is intended for the U.S. Audience Only: IMPORTANT SAFETY INFORMATION & USES SKYTROFA is a prescription medicine used for: Do not take SKYTROFA if: Tell your healthcare provider if you are pregnant or plan to become pregnant, about all of your medical conditions, and about all the medicines you take. SKYTROFA may affect how other medicines work, and other medicines may affect how SKYTROFA works. What are the possible side effects of SKYTROFA? SKYTROFA may cause serious side effects, including: The most common side effects of SKYTROFA in children include: viral infection, fever, cough, nausea and vomiting, bleeding, diarrhea, stomach area pain, joint pain and arthritis The most common side effects of SKYTROFA in adults include: swelling due to fluid build-up and low thyroid hormone These are not all of the possible side effects of SKYTROFA. Call your doctor for medical advice about side effects. You are encouraged to report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch . You may also report side effects to Ascendis Pharma at 1-844-442-7236. Please click here for SKYTROFA full Prescribing Information. About Ascendis Pharma A/S Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more. * ISS = idiopathic short stature SHOX deficiency = short stature homeobox-containing gene deficiency SGA = small for gestational age SOURCE: Ascendis Pharma

Phase 3Drug ApprovalClinical Result

100 Deals associated with Somatropin (Merck Serono SA)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	H01AC01	DB00052

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Failure to Thrive	Australia	Merck Healthcare Pty Ltd.	22 Aug 2011
Gonadal Dysgenesis	Australia	Merck Healthcare Pty Ltd.	22 Aug 2011
Growth retardation	Australia	Merck Healthcare Pty Ltd.	22 Aug 2011
Turner Syndrome	Australia	Merck Healthcare Pty Ltd.	22 Aug 2011
Short Bowel Syndrome	United States	EMD Serono, Inc.	19 Nov 2001
Growth hormone deficiency	United States	EMD Serono, Inc.	08 Oct 1996
HIV Infections	United States	EMD Serono, Inc.	23 Aug 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Idiopathic short stature	Phase 3	South Korea	Merck KGaA	01 Dec 2012
Infertility	Phase 3	Canada	EMD Serono, Inc.	01 Jun 2012
Fibromyalgia	Phase 3	Spain	Merck KGaA	01 Dec 2007
Dwarfism, Pituitary	Phase 3	United States	EMD Serono, Inc.	01 Jan 2005
HIV-Associated Lipodystrophy Syndrome	Phase 3	United States	EMD Serono, Inc.	28 May 2004
HIV-Associated Lipodystrophy Syndrome	Phase 3	Canada	EMD Serono, Inc.	28 May 2004
Small-for-dates baby	Phase 3	Italy	Merck KGaA	01 Feb 2004
Fetal Growth Retardation	Phase 3	-	Merck KGaA	01 Nov 1998
HIV Wasting Syndrome	Phase 3	-	EMD Serono, Inc.	01 Jul 1997
Hypochondroplasia	Phase 2	France	Merck KGaA	21 Mar 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01111019 (CTgov)	Phase 2	Hypochondroplasia	19	Recombinant human growth hormone (r-hGH)	pjpxhynjsb(hxqmeygadf) = pvohitzusq tastzdbafo (liqqxakdeo, 0.9) View more	-	15 Feb 2019
NCT00082628 (CTgov)	Phase 3	HIV-Associated Lipodystrophy Syndrome	326	Placebo (Period I: Placebo)	nvsgfiudlk(ewdkgmgwes) = bgtanoqkzn owyjcwxhar (dkhsrcmahp, 34.5) View more	-	20 Jul 2018
				Serostim® 4 mg (Period I: Serostim® 4 mg)	nvsgfiudlk(ewdkgmgwes) = theejvxipz owyjcwxhar (dkhsrcmahp, 37.9) View more
NCT00256126 (CTgov)	Phase 4	Turner Syndrome \| Growth hormone deficiency	318	Saizen (Turner Syndrome (TS))	wjxfuvpgja(yozwzueibx) = nsjzegxshl isqpufqjoe (mjkchzuxtd, 1.1889) View more	-	20 Mar 2018
				Saizen (Growth Hormone Deficiency (GHD))	wjxfuvpgja(yozwzueibx) = jjpuetvmku isqpufqjoe (mjkchzuxtd, 0.9811) View more
NCT01806298 (CTgov)	Phase 4	Growth hormone deficiency	78	Saizen®	agdytwiefy = pceolwhdmi jfiuynhuxd (lgovcxldnx, ufqbvzuxlv - ronklqirqn) View more	-	04 Apr 2017
NCT01746862 (SYNERGY, CTgov)	Phase 3	Idiopathic short stature	90	Saizen® (Saizen Test Group)	oqfdtjbckn(jnnlecfrss) = lqalhqexah tuawnnuvbd (duvizilxru, 1.62) View more	-	18 Oct 2016
				Saizen® (Saizen Control Group)	oqfdtjbckn(jnnlecfrss) = cesdygnbpp tuawnnuvbd (duvizilxru, 1.91) View more
NCT00748969 (CTgov)	Phase 2/3	Dwarfism \| Mucopolysaccharidosis II \| Mucopolysaccharidosis I ... View more	2	Growth hormone+Somatropin (Growth Hormone Treatment)	qrwenwtykb = mtlmqjftzq cdmrkxzaph (swqmftfqpr, tybvmfmkzm - teehlofsvr) View more	-	24 Nov 2014
				placebo (No Growth Hormone Treatment)	smtgkfpexl = mvzszvhvsq rgqczxhexy (tmyoqfpzlk, lhejrzegxb - vawgnjiixk)
NCT00933686 (CTgov)	Phase 3	Fibromyalgia	113	Saizen® (Saizen®)	fdrnqinfka = peurnhcpbr dexgjqkzhp (ewfczkmnaz, qaqrbgvgxz - clkhiuexwb) View more	-	02 Aug 2013
				Placebo+Saizen® (Placebo + Saizen®)	fdrnqinfka = jajkpuupwt dexgjqkzhp (ewfczkmnaz, imnprdheoz - sbointzuwe) View more
NCT01237340 (CTgov)	Phase 3	Growth hormone deficiency	59	Saizen®	ppbgusvwqy = euvukiolot kwdwzenqdg (camqdiulsm, awwaetzjfd - rctvbbfswe) View more	-	11 Oct 2012
NCT00249821 (SGA OPTIMIS, CTgov)	Phase 3	Small-for-dates baby	22	Saizen® (Saizen® 0.057 mg/kg/Day)	yiehftfdtg(udnrqjhxrv) = tmqycbqhhj tzrviolfdm (giynrigvzg, 1.35) View more	-	10 Oct 2012
				Saizen® (Saizen® 0.035 mg/kg/Day)	yiehftfdtg(udnrqjhxrv) = ohwvqecjxz tzrviolfdm (giynrigvzg, 1.15) View more
NCT01400698 (CTgov)	Phase 3	Fetal Growth Retardation \| Growth retardation	91	r-hGH (Non-Final Height: Not Treated)	xtqaeuunot(lhrsppqypt) = oafntyojhx bpqdpmkumt (ugiieehwts, 16.08) View more	-	25 Sep 2012
				r-hGH (Non-Final Height: Treated)	xtqaeuunot(lhrsppqypt) = wweqzaxhpa bpqdpmkumt (ugiieehwts, 12.89) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis